Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease

Table 3

Summary data of IBD patients with COVID-19 with severe complications.

No.	Age, sex	IBD classification^a	Comorbidity	IBD activity	IBD medications	COVID-19 symptoms	COVID-19 complications	Outcome
1	58, M	CD (A3L3S1)	CHF, HTN, DM, AKI, COPD, DVT, morbid obesity	Inactive (HBI 2)	No IBD medication (previous adalimumab)	Fever, dyspnea	Pneumonia, respiratory failure, hospitalization (ICU) for 44 days	Death
2	47, F	CD (A1L3 + L4S2) after resection with ileostomy	None	Inactive (HBI 2)	Infliximab	Fever, dyspnea, diarrhea	Pneumonia, hospitalization (24 days)	Recovery
3	68, F	CD (A3L2S1)	ESRD, IHD, SCV thrombosis	Inactive (HBI 2)	No IBD medication	Fever, dyspnea	Pneumonia, respiratory failure, hospitalization (ICU) for 3 days	Death
4	60, M	CD after colectomy with IPAA (A1L3S2)	Pancreatic cancer, psoriasis	Active (HBI 5)	No IBD medication	Fatigue, diarrhea, abdominal pain	Diarrhea and fever, AKI hospitalization (6 days)	Recovery
5	59, F	UC (A2E2S2)	None	Active (partial Mayo 8)	Adalimumab, prednisone 50 mg/day	Fever, cough, dyspnea	Pneumonia, hospitalization (5 days)	Recovery
6	50, M	UC (A2E2S3)	Morbid obesity	Active (partial Mayo 5, MES 3)	Oral 5-ASA, prednisone 20 mg/day, tofacitinib	Fever, dyspnea	Pneumonia, hospitalization (4 days)	Recovery

^aIBD classification by Montreal classification. CD: Crohn’s disease, UC: ulcerative colitis, HBI: Harvey-Bradshaw Index, SES-CD: Simplified Endoscopic activity Score for Crohn’s Disease, MES: Mayo endoscopic score, AKI: acute kidney injury, COPD: chronic obstructive pulmonary disease, CHF: congestive heart failure, DVT: deep vein thrombosis, DM: diabetes mellitus, ESRD: end-stage renal failure, HT: hypertension, IHD: ischemic heart disease, SCV: subclavian vein, 5-ASA: 5-aminosalicylic acid, ICU: intensive care unit.